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Abstract. The repurposing of drugs is becoming increasingly 
attractive as it avoids the lengthy process and cost implications 
associated with bringing a novel drug to market. Itraconazole 
is a broad-spectrum anti-fungal agent. An emerging body of 
in vivo, in vitro and clinical evidence have confirmed that it 
also possesses antineoplastic activities and has a synergistic 
action when combined with other chemotherapeutic agents. 
It acts via several mechanisms to prevent tumour growth, 
including inhibition of the Hedgehog pathway, prevention of 
angiogenesis, decreased endothelial cell proliferation, cell 
cycle arrest and induction of auto-phagocytosis. These allow 
itraconazole, either alone or in combination with other cyto-
toxic agents, to increase drug efficacy and overcome drug 
resistance. This study reviews the reported literature on the 
use of itraconazole in a variety of malignancies and highlights 
the recent insights into the critical pathways acted upon to 
prevent tumour growth.
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1. Background
The repurposing of drugs is becoming increasingly attrac-
tive as it avoids the expense and time required to develop 
novel therapeutics (1-3). Itraconazole is a Food and Drug 
Administration-approved agent that has passed toxicity testing, 
has recognised anti-neoplastic properties and has already been 
assessed in cancer therapy (4,5).
The original function of itraconazole was as a 
broad-spectrum anti-fungal agent that inhibits lanosterol 
14-α-demethylase (14LDM), an enzyme that produces ergos-
terol in fungi and cholesterol in mammals (4-8). It is used to 
treat fungal infections, including aspergillosis, candidiasis and 
histoplasmosis, and for prophylaxis in immunosuppressive 
disorders (9,10). Itraconazole is a relatively safe drug, with 
rare side effects, including neutropenia, liver failure and heart 
failure (9).
An emerging body of in vivo, in vitro and clinical evidence 
has confirmed that itraconazole possesses antineoplastic 
activity and has a synergistic action when combined with 
other chemotherapeutic agents (4-33). It acts via several 
underlying mechanisms to prevent tumour growth (Fig. 1), 
including inhibition of the Hedgehog pathway, prevention 
of angiogenesis, decreased endothelial cell proliferation, 
cell cycle arrest, reversal of drug resistance and induction 
of auto-phagocytosis (9-11). Itraconazole's ability to prevent 
angiogenesis appears to be associated with its anti-fungal 
properties, yet all other mechanisms are not associated with 
the inhibition of 14LDM (4-8,12).
This paper reviews the currently available literature 
regarding the use of itraconazole in a variety of malignan-
cies. A literature search was performed using PubMed with 
the keywords ʻItraconazole and Cancerʼ from January 1987 
to October 2016. Those articles with titles relevant to our 
review topic were assessed for eligibility; abstracts that 
either described the clinical use of itraconazole as a cancer 
treatment in patients or illustrated evidence of itraconazole's 
antineoplastic activity from in vivo or in vitro studies were 
included. These selected articles were obtained and analysed 
in full, with 31 included in our review. Fig. 2 demonstrates the 
articles initially identified and those included for the review of 
the literature.
2. Itraconazole and the Hedgehog pathway
The Hedgehog pathway controls necessary developmental 
and embryogenic processes that are involved in tissue 
patterning and morphogenesis (4,11,13). While essentially 
quiescent in adult tissues, the Hedgehog pathway is involved 
in the maintenance of certain epithelial progenitor cell 
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populations and is activated during tissue regeneration and 
wound healing (4,13). In the absence of Sonic Hedgehog 
ligand (Shh), patched 1 (PTCH1) represses the activity 
of smoothened (SMO), and the pathway is turned off. 
Binding of Shh ligand to PTCH1 relieves its suppres-
sion of SMO, resulting in protein stabilisation and nuclear 
translocation of the GLI transcription factors (34-36). The 
GLI proteins, of which there are three (GLI1-3), activate 
a plethora of downstream targets that effect cell growth, 
survival and differentiation (37). In the majority of 
situations, expression of GLI1 mRNA is used as a surrogate 
marker for Hedgehog pathway activity (4). Fig. 3 depicts 
the Hedgehog signalling pathway, when activated and 
supressed.
Abnormalities in Hedgehog signalling can result in 
congenital malformations, and inappropriate activation of 
the pathway may lead to the development of cancer (4,11). 
In addition to the overexpression of Shh, Hedgehog 
pathway activation may follow loss-of-function of PTCH1, 
gain-of-function mutations in SMO and epigenetic 
modulation of key pathway components, such as suppressor 
of fused, which is a negative regulator of the Hedgehog 
pathway (11).
Thus far, drugs designed to treat Hedgehog-driven 
malignancies have been developed to target SMO, although 
other compounds have been identified to inhibit or modulate 
the activity of the GLI proteins (38). Drugs demonstrated 
to block the Hedgehog pathway include vismodegib 
(GDC-0449), sonidegib (LDE-225) and cyclopamine (39). 
These drugs are known to act by binding to and antagonising 
the function of SMO (4,11,14). Itraconazole similarly inhibits 
the Hedgehog pathway by acting directly on SMO but, 
unlike other drugs, it binds to a different site on the SMO 
protein (4,11). This is the likely explanation for its synergistic 
activity with other anti-neoplastic agents, such as vismodegib. 
Itraconazole can therefore be used in combination with or, in 
cases of drug resistance, as an alternative to other Hedgehog 
pathway inhibitors (4). When other signalling pathways 
facilitate neoplastic growth, tumours may survive even in 
the presence of Hedgehog pathway inhibition, and therefore, 
a combination of drugs acting on multiple pathways may be 
required (14).
Evidence from pre-clinical studies has confirmed 
the capacity of itraconazole to inhibit the Hedgehog 
pathway (4,12,13,15,16). Treatment of allografted medullo-
blastomas in a murine model resulted in a reduction in GLI1 
mRNA and growth suppression (4). When combined with 
cyclopamine the effect was greater than with itraconazole 
treatment alone (4,11). Shh and GLI1 expression was revealed 
in low grade, stage 1A human endometrial cancer tissue 
samples (15). In vitro cell proliferation was then significantly 
inhibited by itraconazole, even when cells were treated with 
an oral anti-fungal dose (15). In cultured pleural mesothe-
lioma cells, activated Hedgehog signalling was inhibited 
with itraconazole and arsenic trioxide, an anti-leukaemia 
drug, which is known to target the GLI1 protein (13). The 
two drugs reduced the expression of GLI1, decreased cell 
viability, perturbed cell cycle progression and induced apop-
tosis (13,16). The Hedgehog pathway is aberrantly activated in 
basal cell carcinoma (BCC), due primarily to the presence of 
a mutated or inherited defective PTCH1 gene (6). Itraconazole 
administration reduced the growth of BCC in mouse models, 
decreased the expression of GLI1 mRNA and induced tumour 
necrosis (4).
3. Itraconazole and angiogenesis
The growth of solid tumours is angiogenesis-dependent (8). 
Anti-angiogenic agents are used in cancer therapy, and 
itraconazole has been shown to act on numerous pathways 
necessary for angiogenesis (8). It inhibits vascular endo-
thelial growth factor (VEGF) signalling by preventing 
VEGF binding to the VEGF receptor 2, thereby reducing 
endothelial cell proliferation (5,17). Itraconazole can also 
prevent cell migration, chemotaxis and tube formation, all 
of which are essential for neovascularisation and angiogen-
esis (8).
The suppression of tumour growth with itraconazole 
treatment has been demonstrated in non-small cell lung 
cancer xenografts (8,18). In one such study, growth was 
reduced by 72 and 79% (P<0.001) in two primary xenograft 
models (8). Greater tumour growth suppression was observed 
with combination therapy involving itraconazole and cispl-
atin (8). As well as inhibiting cell proliferation in response 
to angiogenesis factors (VEGF and fibroblast growth factor), 
the migration and formation of tube networks were also 
prevented. These are necessary for capillary bed produc-
tion; therefore, the area of tumour vascularity significantly 
decreased (8,18). In addition, itraconazole has been demon-
strated to reduce pleural effusion volumes, the number of 
pleural tumour foci and VEGF-C levels in xenograft models 
with Lewis lung carcinoma (7).
4. Itraconazole and drug resistance
Drug resistance is a major obstacle in the desire to cure 
malignancies (33). Combination therapy is believed to reduce 
the development of drug resistance when compared with 
treatment with one drug alone (40,41). It is therefore possible 
that itraconazole can prevent the resistance associated 
with monotherapy when combined with other medications. 
Furthermore, all opportunities in reversing resistance should 
be explored, particularly with therapies that have minimal 
sequela, such as itraconazole. It has been revealed in vitro to 
reverse multi-drug resistance in numerous types of malig-
nancies (9). In ovarian and breast cancer, drug resistance 
to chemotherapy is associated with permeability glyco-
protein (also termed p-glycoprotein), multidrug resistance 
protein 1 and ATP-binding cassette sub-family B member 
1 (14,18). This is an efflux pump present on cell membranes 
that reduces intracellular drug concentrations, conferring 
cellular resistance to genotoxic therapies (42). Ovarian 
clear cell carcinoma, one of the more aggressive disease 
subtypes, has been identified to have increased expression 
of these efflux pumps, thereby preventing the accumulation 
of cytotoxic agents within the malignant cells (43). In vitro 
studies confirm that itraconazole inhibits the efflux pump, 
thus reversing resistance (10,14,19,20). This has also been 
observed in resistant leukaemia and human embryonic 
kidney cells (21,22).
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Figure 2. Flow diagram of the literature search. Articles identified, analysed and included in literature review.
Figure 1. The anti-neoplastic activities of itraconazole. A diagram demonstrating the anti-neoplastic activities of itraconazole: Hedgehog pathway inhibition; 
angiogenesis inhibition; autophagy; multi-drug resistance reversal. VEGF, vascular endothelial growth factor; mTOR, mechanistic target of rapamycin; SMO, 
smoothened.
POUNDS et al:  REPURPOSING ITRACONAZOLE FOR THE TREATMENT OF CANCER2590
5. Clinical papers
The use of itraconazole as a therapy has received extensive 
attention, primarily in phase I/II studies. Details of recent 
clinical studies are presented in Table I.
Ovarian cancer. At presentation, ovarian cancer is at an 
advanced stage in 70-75% of patients, and has a 5-year survival 
rate of ~40% (44,45). Although the initial response rates to first 
line chemotherapy are high, resistance is common, as reflected 
by poor survival (46). Itraconazole has been utilised in refrac-
tory disease to try and reverse such chemo-resistance (19,23). 
In a retrospective review, 55 patients were treated either 
with chemotherapy alone (regimes of pegylated liposomal 
doxorubicin, gemcitabine, docetaxel, irinotecan or paclitaxel) 
or chemotherapy (docetaxel based in 79%) combined with 
itraconazole. The combination therapy was given biweekly 
to 19 female patients, with 400-600 mg itraconazole admin-
istered daily for 4 or 5 days. The median progression-free 
survival time was significantly longer for those receiving 
itraconazole (103 days, compared with 53 days in those who 
did not receive itraconazole; P=0.014), as was the overall 
survival time (642 days, compared with 139 days in those who 
did not receive itraconazole; P=0.0006). The overall response 
rate following treatment was 18%, with a greater proportion 
of the itraconazole group exhibiting a response (32% in the 
itraconazole group, 11% in the control group). The continued 
use of itraconazole is the likely explanation for the improved 
survival rates (23).
In another study (19), 9 patients with recurrent clear cell 
ovarian cancer had itraconazole added to their treatment 
regime with the objective of improving chemotherapeutic effi-
cacy. Itraconazole 400 mg daily was administered over 4 days 
every 2 weeks. A response rate of 44% was achieved, with 
a higher median overall survival time (1,047 days) compared 
with that previously reported in other studies, which ranged 
between 7 and 10 months (47,48).
As chemotherapy is typically discontinued following resis-
tance, few patients with refractory disease are eligible for such 
studies, and small numbers of female patients included (49). 
Another limitation is that cytotoxic regimens differ between 
patients, doses are frequently altered and patients are not 
randomised.
Prostate cancer. In advanced prostate cancer, although 
androgen deprivation therapy can be successful, inevitably 
resistance will develop (50). When this occurs, therapeutic 
options are limited. A subsequent randomised phase II trial 
Figure 3. Schematic representation of the Hedgehog signaling pathway. In the absence of Shh, PTCH1 suppresses the activity of SMO. SuFu induces protea-
somal degradation of the GLI (glioma-associated oncogene) transcription factors. The cleaved GLI factors, GLI-R (GLI repressor form), translocate to the 
nucleus where they suppress the expression of Hedgehog target genes. In this setting, the pathway is turned off. In the presence of Shh, PTCH1 suppression 
of SMO is relieved, which modulates SuFu activity. SuFu no longer associates with the GLI transcription factors, which translocate to the nucleus, activating 
Hedgehog target genes. These include pathway effectors (GLI1) and regulators (PTCH1 and HIP), and proteins involved in cell proliferation (PDGRF, cyclin 
D2, BMI1 (B‑cell‑specific Moloney murine leukemia virus integration site 1) and c‑MYC). Hedgehog pathway inhibitors referred to include GDC‑0449 
(vismodegib), LDE225 (erismodegib) and itraconazole, which directly inhibit SMO. Shh, Sonic Hedgehog ligand; PTCH1, patched 1; SMO, smoothened; SuFu, 
suppressor of fused; HIP, Hedgehog interacting protein; PDGFR, platelet-derived growth factor receptor.
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explored the use of either 200 or 600 mg itraconazole daily 
for the treatment of metastatic castration-resistant prostate 
cancer in 46 patients (24). The higher dose increased progres-
sion‑free survival times and prostate‑specific antigen (PSA) 
progression-free survival rates. In addition, skin biopsies 
exhibited a down‑modulation of GLI1 (reflecting inhibition of 
the Hedgehog pathway) in the two treatment arms, which was 
associated with a significantly longer median PSA progres-
sion-free survival time (24).
A further case report describes the use of high dose 
itraconazole (300 mg twice daily) to treat a biochemical 
recurrence following radical prostatectomy in non-metastatic 
disease (25). After the patient declined castration treatment, 
itraconazole was administered and the PSA level reduced by 
>50% in 3 months. Although the PSA continued to decline 
during an additional 2 months of treatment, levels began to 
rise upon termination of the therapy (25). As such, itracon-
azole may be an alternative therapy for those wishing to avoid 
castrating or cytotoxic therapy, although additional trials are 
required to confirm this (24,25).
Breast cancer. A pilot trial evaluated the pharmacokinetics 
of itraconazole when administered to 13 patients with meta-
static breast cancer (26). As the plasma levels of itraconazole 
increased, higher levels of thrombospondin-1, which inhibits 
angiogenesis, were detected. In addition, the levels of 
other angiogenic factors, basic fibroblast growth factor and 
placenta-derived growth factor decreased, albeit lacking a 
direct association between the fall in angiogenic factors and 
itraconazole levels.
In another study, 13 patients with progressive triple-nega-
tive breast cancer, despite extensive chemotherapy, were 
administered itraconazole (27). Patients commenced itra-
conazole treatment (400 mg daily for 4 days, repeated every 
2 weeks) alongside cytotoxic agents, with 5 patients also 
receiving bevacizumab. Response rates were high (62%), with 
23% complete responses. Overall survival rates were advanta-
geous compared with previous findings of itraconazole use. 
Earlier studies of triple-negative disease failed to demonstrate 
such improvements: A phase III trial using bevacizumab and 
a retrospective analysis of platinum-based chemotherapy did 
not reveal overall survival benefits, while a meta-analysis 
identified only short‑term improvements with platinum‑based 
chemotherapy in non-metastatic disease (51-53).
Lung cancer. Itraconazole has been analysed as a second line 
treatment in metastatic non-squamous non-small cell lung 
cancer (18). A phase II study on 23 patients randomised to 
either single agent pemetrexed or combined pemetrexed and 
itraconazole (200 mg daily for 21 day cycles) reported the 
anticipated response rates in the pemetrexed only arm, with 
improved outcomes in those exposed to itraconazole (18). 
The proportion with disease stabilisation at 3 months was 
higher, median progression-free survival increased and 
overall survival was greater compared to those treated with 
pemetrexed alone. Future trials will explore its use as a first 
line treatment alongside other agents.
BCC. BCC, the most common form of skin cancer, has been 
a focus for Hedgehog pathway inhibitors (6,28,29,54,55). 
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Studies using vismodegib, sonidegib and itraconazole to treat 
BCC have all demonstrated efficacious results; however, resis-
tance is frequently problematic (6,28,29,55-58). One phase II 
trial compared high dose itraconazole (200 mg twice daily 
for 4 weeks) with a control group, demonstrating a reduction 
in cell proliferation (Ki-67) and Hedgehog pathway activity 
(GLI1 mRNA levels) with itraconazole (6). The tumour area 
decreased when treated with either the high dose or with a 
lower dose over a longer time period (100 mg twice daily for 
1‑4 months). The findings were not replicated in those with 
prior vismodegib exposure, questioning the value of itracon-
azole following resistance to this drug (6).
Another review also determined that clinical responses 
were limited following vismodegib resistance (29). A total of 
5 patients with metastatic BCC were treated with combined 
itraconazole (400 mg daily on days 6-28) and intravenous 
arsenic trioxide (on days 1-5). Despite a 75% decrease in GLI1 
mRNA levels, a reduction in tumour size was not evident. 
While vismodegib and sonidegib appear to provide higher 
response rates and greater Hedgehog pathway inhibition, it 
may be beneficial to use itraconazole following resistance or 
as a combined therapy. It remains unclear whether continuous 
high dose itraconazole administered over a longer period 
could give similar results to those observed with vismodegib 
and sonidegib (6,28,29).
Pancreatic cancer. In a previous study (30), 38 patients 
with progressive pancreatic cancer received itraconazole 
(400 mg daily for 4 days) in combination with chemotherapy 
(docetaxel, gemcitabine and carboplatin) over 2 week cycles. 
A response rate of 37% was achieved, with complete and 
partial responses in 1 and 13 patients, respectively. In total, 
35 patients who either had stable disease or had a complete 
or partial response continued itraconazole treatment with 
irinotecan-based chemotherapy. The response rate increased to 
47%, with a median overall survival time of 11.4 months. This 
was greater than the median overall survival time of 6 months 
found in an earlier analysis of clinical trials that investigated 
second-line treatment in advanced pancreatic disease (59). 
The advantageous results in this study are possibly due to the 
administration of triple chemotherapeutic agents.
A serendipitous case of pancreatic cancer treated by itra-
conazole has previously been reported (10). Histoplasmosis 
infection was detected in a patient with stage III locally 
advanced unresectable pancreatic adenocarcinoma. Palliative 
chemotherapy was paused, a 9-month course of itraconazole 
200 mg daily commenced and, upon completion, the tumour 
was revealed to have decreased in size. It was deemed resect-
able and following surgery the patient remained disease free, 
with no evidence of recurrence. As chemotherapy had been 
withheld, the reduction was thought to have been caused by 
itraconazole and Hedgehog pathway inhibition.
Biliary tract cancer. Biliary tract cancer is a rare condition 
and has a poor prognosis (60). Favourable response rates and 
acceptable toxicity effects have been demonstrated in a study 
of patients with refractory metastatic biliary tract carcinoma 
treated with itraconazole (31). A total of 28 patients received 
itraconazole (400 mg daily for 4 days) in addition to chemo-
therapy regimens (docetaxel, gemcitabine and carboplatin 
in 26 patients, docetaxel and irinotecan in 2 patients). A 
complete response was observed in 2 patients, while 14 had 
a partial response. The overall response rate was 57% and the 
median overall survival time was 12 months. This compares 
to 7.2 months in a systematic review of second-line treatment 
for advanced biliary tract carcinoma (61). Despite the small 
number of patients in this study, itraconazole appears to be a 
promising therapeutic alternative after first‑line treatment in 
recurrent disease.
Mycosis fungoides. Another study on successful itraconazole 
treatment is that of a patient with Mycosis fungoides (32), the 
most common type of cutaneous T-cell lymphoma. The patient 
developed erythematous plaques on four separate occasions, 
yet no cause was identified. Following no improvement with 
miconazole or topical steroids, itraconazole 200 mg daily 
was administered for 7 days. The lesions completely resolved 
and additional episodes again only responded following itra-
conazole treatment. Eventually biopsy and histology results 
supported a diagnosis of Mycosis fungoides. The mechanism 
of action in this condition is unclear.
Acute leukaemia. As previously stated, itraconazole is used 
for fungal infection prophylaxis in immunosuppressive 
conditions (9). In patients with acute leukaemia it is often 
administered for prophylactic purposes in those receiving 
chemotherapy (33,62). Resistance to the cytotoxic agent 
daunorubicin has been reversed by itraconazole (63). It has 
been demonstrated that the addition of itraconazole (100 mg 
twice daily) improves remission rates in acute myelogenous 
leukaemia and disease-free survival in acute lymphoblastic 
leukaemia (33). This supports itraconazole's action of reversing 
drug resistance and is considered to be associated with its 
involvement with cytochrome P-450 and P-glycoprotein.
6. Conclusion
There is understandable reticence regarding the repurposing 
of drugs. Although the initial focus of these therapies is to 
treat non-malignant disease, the principle of cell destruction 
and elimination is the same as in agents created to target 
malignancy. To have a drug acting singularly on a recognised 
essential pathway in the malignant process is ideal, but, in 
reality, few drugs act in such a manner. Thus, the use of thera-
pies with multiple targets would be reasonable to explore.
Treatments that cause fewer adverse effects, give greater 
survival benefits and are more cost-effective are greatly 
required (8). Itraconazole has been shown to be safe in humans 
and is cheap to purchase, thus making it a viable option for 
future studies (9,23). By avoiding the lengthy process and 
cost-implications associated with bringing a novel drug to 
market, further study into its actions and potential benefits 
make it an attractive prospect.
Evidence from in vivo, in vitro and clinical studies have 
demonstrated the antineoplastic effects of itraconazole and 
have revealed at a number of the critical pathways that it 
targets (4-33). These results allow itraconazole, alone or in 
combination with other chemotherapeutic agents, to increase 
drug efficacy and overcome drug resistance. Exploration in 
aggressive and refractory disease, including ovarian cancer, 
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with greater participant numbers and consistent treatment 
regimens is required. While trials are currently underway and 
additional studies are planned, studies need to use itraconazole 
in combination with other drugs affecting cell survival. They 
need to use itraconazole over longer time periods, at various 
stages of disease, in tumours associated with drug resistance 
and in other malignancies known to be affected by the 
Hedgehog pathway and angiogenesis (9,10).
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